Koala Chlamydia Vaccine Study Under Scrutiny
"We don't know if it works or not, and that means more research needs to be done, and it needs to be done correctly."
— Professor Keith Chappell, University of Queensland molecular virologist
Key Concerns Raised
A University of Queensland molecular virologist has cast doubt on the findings of a koala chlamydia vaccine study led by researchers at the University of Sunshine Coast.
Professor Keith Chappell questioned the study's central claim that the vaccine enabled koalas to survive to age 10 or 11. He pointed out that the data did not support this conclusion, as the vaccine was administered at that age, not before.
University Acknowledges Errors
A spokesperson for the University of the Sunshine Coast conceded there were "minor errors" in the peer-reviewed study, which was published in NPJ Vaccines.
However, the spokesperson maintained that the findings still showed a significant difference between vaccinated and unvaccinated koalas in reducing disease development.
But here's the critical issue: after removing the problematic data points, the protection from death was no longer statistically significant—due to the reduced sample size.
Funding and Registration
The research received substantial public funding:
- Federal government: $749,000
- Queensland government: $100,000
The vaccine, named Klavax, was registered with the Australian Pesticides and Veterinary Medicines Authority in 2024. At the time, federal environment minister Murray Watt described it as "historic", stating:
"We knew a single-dose vaccine... was the answer to reducing the rapid, devastating spread of this disease."
Broader Context
Koala chlamydia is a major threat to the endangered species, causing both infertility and death. Professor Timms had been working on the vaccine for over a decade.
The university confirmed that vaccine production has not been suspended, but a new batch is currently being produced for APVMA-approved testing.
The Path Forward
Professor Chappell recommended further research to determine the vaccine's true efficacy. He also emphasized the need to address broader threats to koalas:
Habitat loss, drought, and bushfires remain significant dangers that require urgent attention alongside any disease management strategy.
USC spokesperson's defense of the research: "This work, undertaken over more than a decade, reflects deep expertise, robust governance and a clear commitment to evidence‑based research."